FDA OKs Edwards' Perimount Magna heart valve:
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale Edwards Lifesciences' Carpentier-Edwards Perimount Magna tissue heart valve for replacing diseased or defective valves. The aortic pericardial bioprosthesis is specifically designed to optimise blood flow for the patient, said the Irvine, California firm. In addition, it is configured to facilitate placement above the patient's native annulus, and its streamlined sewing ring maximises the valve size that can be implanted. It is also treated with Edwards' proprietary XenoLogiX tissue treatment, which removes phospholipids from the bovine pericardial tissue. The product will be released in a limited capacity during the current quarter, followed by a full-scale launch in 2004. Edwards estimates the heart valve repair and replacement market to be worth $900m.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.